Extrapolating:
Imagine a highly speculative scenario where:
- FTO is ~15% of all cancers (versus 5% above) and RAC already have 3 initial indications progressing (AML, Melanoma, ccRCC)
- USD $380M x 3 = USD $1,140 upfront ( AUD $1.6B )
(I'd prefer RAC to pursue deals with zero equity)- USD $1.3B x 3 = USD $3.9M ( AUD $5.5B )
Then rinse-repeat for other indications / formulations (cardio-protective, Zantrene high-dose, Pillar 3)
- RAC receives AUD $1.6B upfront and distributes 50-75% of this to shareholders, keeping cash in bank to fund aggressive set of trials. This would be a distribution of AUD $800M to AUD $1.2B to shareholders.
- RAC then over the course of several years distribute a further AUD $5.5B to shareholders due to contingent milestones
- Some of these transactions potentially including royalties on future sales ... ?!
Industry news, page-423
-
- There are more pages in this discussion • 1,348 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.105(6.14%) |
Mkt cap ! $309.0M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $862.1K | 467.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |